Anti-Bacterial Agents/therapeutic use; Drug Monitoring/methods; Humans; Intensive Care Units; Internationality; Surveys and Questionnaires; beta-Lactams/therapeutic use; TDM; antimicrobial; critical care; dosing; pharmacokinetics
Abstract :
[en] OBJECTIVES: Emerging evidence supports the use of therapeutic drug monitoring (TDM) of beta-lactams for intensive care unit (ICU) patients to optimize drug exposure, although limited detail is available on how sites run this service in practice. This multicentre survey study was performed to describe the various approaches used for beta-lactam TDM in ICUs. METHODS: A questionnaire survey was developed to describe various aspects relating to the conduct of beta-lactam TDM in an ICU setting. Data sought included: beta-lactams chosen for TDM, inclusion criteria for selecting patients, blood sampling strategy, analytical methods, pharmacokinetic (PK)/pharmacodynamic (PD) targets and dose adjustment strategies. RESULTS: Nine ICUs were included in this survey. Respondents were either ICU or infectious disease physicians, pharmacists or clinical pharmacologists. Piperacillin (co-formulated with tazobactam) and meropenem (100% of units surveyed) were the beta-lactams most commonly subject to TDM, followed by ceftazidime (78%), ceftriaxone (43%) and cefazolin (43%). Different chromatographic and microbiological methods were used for assay of beta-lactam concentrations in blood and other biological fluids (e.g. CSF). There was significant variation in the PK/PD targets (100% fT>MIC up to 100% fT>4xMIC) and dose adjustment strategies used by each of the sites. CONCLUSIONS: Large variations were found in the type of beta-lactams tested, the patients selected for TDM and drug assay methods. Significant variation observed in the PK/PD targets and dose adjustment strategies used supports the need for further studies that robustly define PK/PD targets for ICU patients to ensure a greater consistency of practice for dose adjustment strategies for optimizing beta-lactam dosing with TDM.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Wong, Gloria
Brinkman, Alexander
Benefield, Russell J.
Carlier, Mieke
De Waele, Jan J.
El Helali, Najoua
Frey, Otto
Harbarth, Stephan
Huttner, Angela
McWhinney, Brett
Misset, Benoît ; Centre Hospitalier Universitaire de Liège - CHU > Service de Soins Intensifs
Touw DJ, Neef C, Thomson AH et al. Cost-effectiveness of therapeutic drug monitoring-a systematic review. Ther Drug Monit 2005; 27: 10-7.
Lorenzen JM, Broll M, Kaever V et al. Pharmacokinetics of ampicillin/ sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012; 7: 385-90.
Chapuis TM, Giannoni E, Majcherczyk PA et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010; 14: R51.
Smith NL, Freebairn RC, Park MAJ et al. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Crit Care Resusc 2012; 14: 312-5.
Udy AA, Varghese JM, Altukroni M et al. Sub-therapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
Taccone FS, Laterre P-F, Dugernier T et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
Ulldemolins M, Roberts JA, Wallis SC et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771-8.
Roberts JA, Paul SK, Akova M et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2013; in press.
Roberts JA, Ulldemolins M, Roberts MS et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332-9.
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-51.
Harbarth S, Garbino J, Pugin J et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
Legrand M, Max A, Peigne V et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40: 43-9.
MacArthur R, Miller M, Albertson T et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38: 284-8.
Hites M, Taccone FS, Wolff F et al. Drug monitoring of β-lactams in obese critically ill patients: a case-control study. Antimicrob Agents Chemother 2013; 57: 708-15.
Patel BM, Paratz J, See NC et al. Therapeutic drug monitoring of β-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit 2012; 34: 160-4.
Ariano RE, Nyhlén A, Donnelly JP et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8.
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
Taccone FS, Hites M, Beumier M et al. Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep 2011; 13: 406-15.
Hayashi Y, Lipman J, Udy AA et al. β-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 2013; 41: 162-6.
Taccone FS, Cotton F, Roisin S et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-31.
Pea F, Cojutti P, Sbrojavacca R et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011; 45: e37.
Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance-implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
Schmitt G, Herbold M, Peters F-T. Valistat-software for method validation in forensic toxicology. Toxichem Krimtech 2011; 78: 392-5.
Peters F-T, Hallbach J, Maurer HH. Empfehlungen des Arbeitskreises Klinische Toxikologie der GTFCh zur Validierung von Methoden fü r die toxikologische Analytik im Rahmen der Hirntod-Feststellung. Toxichem Krimtech 2009; 76: 232-6.
Wolff F, Deprez G, Seyler L et al. Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta 2013; 103: 153-60.
McWhinney BC, Wallis SC, Hillister T et al. Analysis of 12 β-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B 2010; 878: 2036-43.
Briscoe SE, McWhinney BC, Lipman J et al. A method for determining the free (unbound) concentration of ten β-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B 2012; 907: 178-84.
Bias M, Frey OR, Kö berer A. HPLC-Methode zur quantitativen Bestimmung von Meropenem im Serum. Krankenhauspharmazie 2010; 31: 482-5.
Hanes SD, Herring VL,Wood GC. Alternative method for determination of ceftazidime in plasma by high-performance liquid chromatography. J Chromatogr B 1998; 719: 245-50.
Mendez ASL, Steppe M, Schapoval EES. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal 2003; 33: 947-54.
Carlier M, Stove V, Roberts JA et al. Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012; 40: 416-22.
Ohmori T, Suzuki A, Niwa T et al. Simultaneous determination of eight β-lactam antibiotics in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2011; 879: 1038-42.
Dumartin C, L'Hériteau F, Péfau M et al. Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007. J Antimicrob Chemother 2010; 65: 2028-36.
Kanerva M, Ollgren J, Lyytikainen O. Antimicrobial use in Finnish acute care hospitals: data from national prevalence survey, 2005. J Antimicrob Chemother 2007; 60: 440-4.
Malacarne P, Rossi C, Bertolini G. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother 2004; 54: 221-4.
Nagy E, Urbán E, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011; 17: 371-9.
European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Consumption in Europe, 2010. Stockholm: ECDC, 2013; 43-51.
Meyer E, Schwab F, Schroeren-Boersch B et al. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 2010; 14: R113.
Dulhunty JM, Peterson DL, Webb SAR et al. Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. Anesth Intensive Care 2011; 39: 231-7.
Bilgrami I, Roberts JA, Wallis SC et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010; 54: 2974-8.
Binder L, Schwörer H, Hoppe S et al. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit 2013; 35: 63-70.
Blondiaux N,Wallet F, Favory R et al. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010; 35: 500-3.
Boselli E, Breilh D, Rimmelé T et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care 2008; 36: 1500-6.
Dailly E, Pannier M, Jolliet P et al. Population pharmacokinetics of ceftazidime in burn patients. Br J Clin Pharmacol 2003; 56: 629-34.
Garot D, Respaud R, Lanotte P et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 2011; 72: 758-67.
Georges B, Conil J-M, Ruiz S et al. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol 2012; 73: 588-96.
Gómez CMH, Cordingly JJ, Palazzo MGA. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43: 1798-802.
Kushner I. The phenomenon of the acute phase response. Ann N YAcad Sci 1982; 389: 39-48.
SAFE Study Investigators, Finfer S, Bellomo R et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006; 333: 1044-9.
Wong G, Briscoe S, Adnan S et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations. Antimicrob Agents Chemother 2013; 57: 6165-70.
Bakker-Woudenberg IAJM, ten Kate MT, Goessens WHF et al. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 2006; 50: 2919-25.
Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
Nicolau DP. Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care 2008; 12: S2.
Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chermother 2002; 50: 425-8.
Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-6.
Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996; 95: 611-2.
Reichardt P, HandrickW, Linke A et al. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment-a retrospective analysis in 38 children with cystic fibrosis. Infection 1999; 27: 355-6.
Lamoth F, Buclin T, Pascual A et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010; 54: 4360-7.
Pea F, Viale P, Cojutti P et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/ pharmacodynamics-based approach. Antimicrob Agents Chemother 2012; 56: 6343-8.
Optimum Dosing Strategies. Individually Designed Optimum Dosing Strategies (ID-ODS). http://www.optimum-dosing-strategies.org/id-ods-1/ (4 August 2013, date last accessed).
Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 1998; 46: 95-9.
American Society of Health-System Pharmacists. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36.
